Results 231 to 240 of about 2,223,665 (257)

DDX42 Enhances Hepatocellular Carcinoma Cell Proliferation, Radiation and Sorafenib Resistance via Regulating GRB2 RNA Maturation and Activating PI3K/AKT Pathway. [PDF]

J Cell Mol Med
Liu Z, Yuan J, Liu F, Zeng Q, Wu Z, Yang J.   +5 more
europepmc   +1 more source

Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity [PDF]

Cancers, 2020
Despite advances in biomedicine, the incidence and the mortality of hepatocellular carcinoma (HCC) remain high. The majority of HCC cases are diagnosed in later stages leading to the less than optimal outcome of the treatments. Molecular targeted therapy with sorafenib, a dual-target inhibitor targeting the serine-threonine kinase Raf and the tyrosine ...
Claudio Tiribelli, Loraine Kay Cabral, Caecilia Sukowati   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

HBx Modulates Drug Resistance of Sorafenib-Resistant Hepatocellular Carcinoma Cells

Discovery Medicine, 2023
Approximately 50% of hepatocellular carcinoma (HCC) arises due to the infection by hepatitis B virus X protein (HBx). Sorafenib, a unique targeted oral kinase inhibitor, is the therapeutic agent of choice for advanced HCC. The mechanism of HBx in drug resistance of sorafenib-resistant HCC cells was evaluated in this study.Employing a stepwise increase ...
Yaping, Liu, Xu, Liu, Miaosha, Luo, Yarui, Li, Hongxia, Li   +4 more
openaire   +2 more sources

New knowledge of the mechanisms of sorafenib resistance in liver cancer [PDF]

Acta Pharmacologica Sinica, 2017
Sorafenib is an oral multikinase inhibitor that suppresses tumor cell proliferation and angiogenesis and promotes tumor cell apoptosis. It was approved by the FDA for the treatment of advanced renal cell carcinoma in 2006, and as a unique target drug for advanced hepatocellular carcinoma (HCC) in 2007.
Hongyang Wang
exaly   +3 more sources

Molecular mechanisms of HCG18 in the sorafenib resistance of hepatocellular carcinoma

Anti-Cancer Drugs, 2023
Sorafenib has been approved for advance hepatocellular carcinoma (HCC), however, drug resistance often occurred. Therefore, it is of great significance to clarify the underlying mechanisms of sorafenib resistance and to find out the effective strategies to overcome sorafenib resistance.
Heping, Li, Jie, Hu, Lijie, Qiu, Yijiang, Wu, Baiyin, Zhong, Rong, Ye, Binhui, Xie   +6 more
openaire   +2 more sources

Sorafenib resistance and therapeutic strategies in hepatocellular carcinoma

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Hepatocellular carcinoma (HCC) remains one of the most prevalent and lethal cancers globally. While surgical resection and liver transplantation offer potential cures for early-stage HCC, the majority of patients are diagnosed at advanced stages where such interventions are not viable.
Weijing, Zhang, Xuechuan, Hong, Yuling, Xiao, Hongbo, Wang, Xiaodong, Zeng   +4 more
openaire   +2 more sources

Sorafenib for hepatocellular carcinoma: potential molecular targets and resistance mechanisms

Journal of Chemotherapy, 2021
Hepatocellular carcinoma (HCC) is the most widespread typical therapy-resistant, unresectable type of malignant solid tumour with a high death rate constituting huge medical concern. Sorafenib is a small molecule oral multi-target kinase potent inhibitor that acts by suppressing/blocking the multiplication of the tumour cells, angiogenesis, and ...
Mandeep, Dahiya, Harish, Dureja
openaire   +2 more sources

Mechanisms of sorafenib resistance in hepatocellular carcinoma

Clinics and Research in Hepatology and Gastroenterology
Liver cancer is one of the most common and devastating causes of cancer-related deaths worldwide. Hepatocellular carcinoma (HCC) accounts for approximately 90% of primary liver cancers and represents a significant global health issue. There is currently no effective systemic treatment for patients with advanced liver cancer.
exaly   +3 more sources

Stabilization of snail maintains the sorafenib resistance of hepatocellular carcinoma cells

Archives of Biochemistry and Biophysics, 2021
Drug resistance is one of the major challenges for treatment of hepatocellular carcinoma (HCC) with sorafenib. Our present study found that sorafenib resistant (SR) HCC cells showed epithelial-mesenchymal transition (EMT) characteristics with the downregulation of epithelial marker and upregulation of mesenchymal makers. The expression of Snail, a core
Huan, Zhao, Xi, Cheng, Judian, Yu, Yong, Li   +3 more
openaire   +2 more sources

Role of Sorafenib in Overcoming Resistance of Chemotherapy-Failure Castration-Resistant Prostate Cancer

Clinical Genitourinary Cancer, 2014
Sorafenib promotes apoptosis through downstream pathways that can be deregulated in CRPC. We hypothesized that sorafenib could overcome chemotherapy resistance in CRPC.Eligible patients were those whose disease had progressed during chemotherapy (docetaxel or mitoxantrone) or within 12 weeks of stopping either.
Andrew, Meyer, Peter, Cygan, Kathy, Tolzien, Angel G, Galvez, Jacob D, Bitran, Timothy M, Lestingi, Chadi, Nabhan   +6 more
openaire   +2 more sources